Suppression of the uPAR-uPA system retards angiogenesis, invasion, and in vivo tumor development in pancreatic cancer cells

Molecular Cancer Research

Volumn 9, Issue 4, 2011, Pages 377-389

  Gorantla, Bharathi ^a   Asuthkar, Swapna ^a   Rao, Jasti S ^a,b   Patel, Jitendra ^c   Gondi, Christopher S ^a  

^a Departments of Pharmacology and Cancer Biology   (United States)

^b Departments of Neurosurgery   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; ANGIOGENIN; CASPASE 8; MESSENGER RNA; RANTES; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR LHX 2; UNCLASSIFIED DRUG; UROKINASE; UROKINASE RECEPTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CARCINOGENESIS; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL DEATH; DOWN REGULATION; ENZYME ACTIVATION; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MOUSE; NICK END LABELING; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RNA INTERFERENCE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; ASPARTATE CARBAMOYLTRANSFERASE; CARBAMOYL-PHOSPHATE SYNTHASE (GLUTAMINE-HYDROLYZING); CARCINOMA, PANCREATIC DUCTAL; CASPASE 8; CELL LINE, TUMOR; CHEMOKINE CCL5; DIHYDROOROTASE; GENE TARGETING; HOMEODOMAIN PROTEINS; HUMANS; MICE; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RIBONUCLEASE, PANCREATIC; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

AGOUTI PACA;

EID: 79954455085     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-10-0452     Document Type: Article

References (42)

1. Ghaneh P, Costello E, Neoptolemos JP. Biology and management of pancreatic cancer. Gut 2007;56:1134-52. (Pubitemid 47123247)
2. Demols A, Peeters M, Polus M, Marechal R, Gay F, Monsaert E, et al. Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br J Cancer 2006;94:481-5. (Pubitemid 43289750)
3. Shaib YH, Davila JA, El-Serag HB. The epidemiology of pancreatic cancer in the United States: changes below the surface. Aliment Pharmacol Ther 2006;24:87-94. (Pubitemid 43894008)
4. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
5. Postier RG. The challenge of pancreatic cancer. Am J Surg 2003;186:579-82. (Pubitemid 37522088)
6. He Y, Liu XD, Chen ZY, Zhu J, Xiong Y, Li K, et al. Interaction between cancer cells and stromal fibroblasts is required for activation of the uPAR-uPA-MMP-2 cascade in pancreatic cancer metastasis. Clin Cancer Res 2007;13:3115-24. (Pubitemid 46944892)
7. Bauer TW, Liu W, Fan F, Camp ER, Yang A, Somcio RJ, et al. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor- mediated migration and invasion and orthotopic tumor growth in mice. Cancer Res 2005;65:7775-81. (Pubitemid 41297252)
8. Ghaneh P, Kawesha A, Evans JD, Neoptolemos JP. Molecular prognostic markers in pancreatic cancer. J Hepatobiliary Pancreat Surg 2002;9:1-11. (Pubitemid 34477366)
9. Gocheva V, Zeng W, Ke D, Klimstra D, Reinheckel T, Peters C, et al. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev 2006;20:543-56. (Pubitemid 43345321)
10. Hildenbrand R, Niedergethmann M, Marx A, Belharazem D, Allgayer H, Schleger C, et al. Amplification of the urokinase-type plasminogen activator receptor (uPAR) gene in ductal pancreatic carcinomas identifies a clinically high-risk group. Am J Pathol 2009;174:2246-53.
11. Xue A, Scarlett CJ, Jackson CJ, Allen BJ, Smith RC. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma. Pancreas 2008;36:160-7.
12. Rao JS. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 2003;3:489-501. (Pubitemid 37328837)
13. Sidenius N, Blasi F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 2003;22:205-22. (Pubitemid 36561058)
14. Kugler MC, Wei Y, Chapman HA. Urokinase receptor and integrin interactions. Curr Pharm Des 2003;9:1565-74. (Pubitemid 36758315)
15. Mahoney TS, Weyrich AS, Dixon DA, McIntyre T, Prescott SM, Zimmerman GA. Cell adhesion regulates gene expression at translational checkpoints in human myeloid leukocytes. Proc Natl Acad Sci U S A 2001;98:10284-9. (Pubitemid 32803012)
16. Dogra C, Changotra H, Wergedal JE, Kumar A. Regulation of phosphatidylinositol 3-kinase (PI3K)/Akt and nuclear factor-kappa B signaling pathways in dystrophin-deficient skeletal muscle in response to mechanical stretch. J Cell Physiol 2006;208:575-85. (Pubitemid 44141882)
17. Kiyan J, Kiyan R, Haller H, Dumler I. Urokinase-induced signaling in human vascular smooth muscle cells is mediated by PDGFR-beta. EMBO J 2005;24:1787-97. (Pubitemid 40769498)
18. Gondi CS, Kandhukuri N, Dinh DH, Gujrati M, Rao JS. Down-regulation of uPAR and uPA activates caspase-mediated apoptosis and inhibits the PI3K/AKT pathway. Int J Oncol 2007;31:19-27.
19. Gondi CS, Lakka SS, Dinh DH, Olivero WC, Gujrati M, Rao JS. Intraperitoneal injection of an hpRNA-expressing plasmid targeting uPAR and uPA retards angiogenesis and inhibits intracranial tumor growth in nude mice. Clin Cancer Res 2007;13:4051-60. (Pubitemid 47105965)
20. Yamamoto M, Sawaya R, Mohanam S, Bindal AK, Bruner JM, Oka K, et al. Expression and localization of urokinase-type plasminogen activator in human astrocytomas in vivo. Cancer Res 1994;54: 3656-61. (Pubitemid 24241173)
21. Mohanam S, Chintala SK, Go Y, Bhattacharya A, Venkaiah B, Boyd D, et al. In vitro inhibition of human glioblastoma cell line invasiveness by antisense uPA receptor. Oncogene 1997;14:1351-9. (Pubitemid 27151992)
22. Leunig M, Yuan F, Menger MD, Boucher Y, Goetz AE, Messmer K, et al. Angiogenesis, microvascular architecture, microhemodynamics, and interstitial fluid pressure during early growth of human adenocarcinoma LS174T in SCID mice. Cancer Res 1992;52:6553-60.
23. Mohanam S, Sawaya R, McCutcheon I, Ali-Osman F, Boyd D, Rao JS. Modulation of in vitro invasion of human glioblastoma cells by urokinase- type plasminogen activator receptor antibody. Cancer Res 1993;53:4143-7. (Pubitemid 24146755)
24. Fu X, Guadagni F, Hoffman RM. A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens. Proc Natl Acad Sci U S A 1992; 89:5645-9.
25. Katz MH, Takimoto S, Spivack D, Moossa AR, Hoffman RM, Bouvet M. A novel red fluorescent protein orthotopic pancreatic cancer model for the preclinical evaluation of chemotherapeutics. J Surg Res 2003;113:151-60. (Pubitemid 36999806)
26. Gondi CS, Rao JS. Therapeutic potential of siRNA-mediated targeting of urokinase plasminogen activator, its receptor, and matrix metalloproteinases. Methods Mol Biol 2009;487:267-81.
27. Kargiotis O, Chetty C, Gogineni V, Gondi CS, Pulukuri SM, Kyritsis AP, et al. uPA/uPAR downregulation inhibits radiation-induced migration, invasion and angiogenesis in IOMM-Lee meningioma cells and decreases tumor growth in vivo. Int J Oncol 2008;33:937-47.
28. Kondraganti S, Gondi CS, McCutcheon I, Dinh DH, Gujrati M, Rao JS, et al. RNAi-mediated downregulation of urokinase plasminogen activator and its receptor in human meningioma cells inhibits tumor invasion and growth. Int J Oncol 2006;28:1353-60.
29. Kunigal S, Lakka SS, Gondi CS, Estes N, Rao JS. RNAi-mediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease-9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growth. Int J Cancer 2007;121:2307-16. (Pubitemid 47585614)
30. Subramanian R, Gondi CS, Lakka SS, Jutla A, Rao JS. siRNAmediated simultaneous downregulation of uPA and its receptor inhibits angiogenesis and invasiveness triggering apoptosis in breast cancer cells. Int J Oncol 2006;28:831-9.
31. Nowicki TS, Kummer NT, Iacob C, Suslina N, Schaefer S, Schantz S, et al. Inhibition of uPAR and uPA reduces invasion in papillary thyroid carcinoma cells. Laryngoscope 2010;120:1383-90.
32. Duriseti KS, Goetz DH, Hostetter DR, Wei Y, Craik CS. Antagonstic anti-upar antibodies significantly inhibit uPAR-mediated cellular signaling and migration. J Biol Chem 2010. [Epub ahead of print].
33. Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000;57:25-40. (Pubitemid 30105328)
34. Sharma MR, Koltowski L, Ownbey RT, Tuszynski GP, Sharma MC. Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression. Exp Mol Pathol 2006;81:146-56. (Pubitemid 44715786)
35. Kim CK, Hong SH, Joe YA, Shim BS, Lee SK, Hong YK. The recombinant kringle domain of urokinase plasminogen activator inhibits in vivo malignant glioma growth. Cancer Sci 2007;98:253-8. (Pubitemid 44941879)
36. Montuori N, Ragno P. Multiple activities of a multifaceted receptor: roles of cleaved and soluble uPAR. Front Biosci 2009;14:2494-503.
37. Lapteva N, Huang XF. CCL5 as an adjuvant for cancer immunotherapy. Expert Opin Biol Ther 2010;10:725-33.
38. Carr MW, Roth SJ, Luther E, Rose SS, Springer TA. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci U S A 1994;91:3652-6. (Pubitemid 24139489)
39. Chang MS, McNinch J, Basu R, Simonet S. Cloning and characterization of the human neutrophil-activating peptide (ENA-78) gene. J Biol Chem 1994;269:25277-82. (Pubitemid 24336204)
40. Persson T, Monsef N, Andersson P, Bjartell A, Malm J, Calafat J, et al. Expression of the neutrophil-activating CXC chemokine ENA-78/ CXCL5 by human eosinophils. Clin Exp Allergy 2003;33:531-7. (Pubitemid 36520920)
41. Wente MN, Keane MP, Burdick MD, Friess H, Büchler MW, Ceyhan GO, et al. Blockade of the chemokine receptor CXCR2 inhibits pancreatic cancer cell-induced angiogenesis. Cancer Lett 2006;241: 221-7. (Pubitemid 44163040)
42. Tiede S, Paus R. Lhx2-decisive role in epithelial stem cell maintenance, or just the "tip of the iceberg"? Bioessays 2006;28:1157-60. (Pubitemid 44925434)